# Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases

> **NCT00106054** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 2 (actual)

## Conditions studied

- Colorectal Neoplasms
- Liver Neoplasms

## Interventions

- **DRUG:** Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.

## Key facts

- **NCT ID:** NCT00106054
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** After 1 year only 2 subjects enrolled and treated thus no meaningful efficacy analyses could be performed.
- **Last updated:** 2010-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106054, "Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00106054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*